Search

Conflict of interest: No Introduction and Objectives: Transient elastography (TE) is an alternative diagnostic tool for estimating liver steatosis and fibrosis. Two ET devices, iLivTouch®/UAP and Fibroscan®/CAP, have shown similar diagnostic accuracy; however, no studies have evaluated the correlation of liver steatosis and fibrosis measurements between both devices in the Mexican population. Aim: To evaluate the correlation of measurement values of liver steatosis and liver fibrosis using iLivTouch®/UAP and Fibroscan®/CAP. Patients / Materials and Methods: This prospective study included adult patients who attended a check-up unit. The evaluation of liver steatosis and liver fibrosis was performed using TE with two devices (iLivTouch® FT100 and Fibroscan® 502 Touch), meeting the reliability parameters. The correlation of measurements was evaluated with the Pearson correlation coefficient; meanwhile, a Student's t-test was performed to determine differences in dB/m and kPa means. Results and Discussion: A total of 69 patients were included; 57% (n=40) were men, with a mean age and body mass index of 45±10 years and 22.4±4.5 kg/m2, respectively. The prevalence of diabetes mellitus was 7.2% (n=5). The mean dB/m and kPa were 266±42 dB/m and 5.8±1.2 kPa with iLivTouch® and 243±56 dB/m and 4.0±0.8 kPa with Fibroscan®. The prevalence of liver steatosis was 29% (n=20) by iLivTouch® and 20% (n=14) by Fibroscan® (p=0.32), while fibrosis was 49.3% (n=34) and 2.9%. (n=2), respectively, (p=0.0001). The mean difference for dB/m was -22.6, p≤0.0001, while for kPa, the difference was 1.72, p≤0.0001. According to the correlation analysis, this was r=0.73 (strong), p≤0.0001 for the estimation of liver steatosis, and r=0.35 (moderate), p=0.003 for the estimation of liver fibrosis. Conclusions: TE devices iLivTouch® and Fibroscan® show a strong correlation for estimating liver steatosis and a moderate correlation for estimating liver fibrosis.

Introduction and Objectives: Liver function tests (LFT) abnormalities are reported in up to 50% of COVID-19 patients, and metabolic comorbidities are associated with poorer outcomes. The aim of the study was to determine the prevalence of liver steatosis and fibrosis in patients with COVID-19 and their association with clinical outcomes. Material and methods: Retrospective study in hospitalized COVID-19 patients was conducted. The risk for liver steatosis was estimated by HSI > 36, and risk for advanced liver fibrosis with APRI > 1.0, NAFLD FS > 0.675 and/or FIB-4 > 3.25. Clinical outcomes were admission to Intensive Care Unit (ICU) and mortality. Results: Of 155 patients, 71.6% were male (n = 111), and 28.4% (n = 44) were obese. Abnormal LFT were present in 96.8% (n = 150), prevalence of steatosis was 42.6% (n = 66) and of significative liver fibrosis was 44.5% (n = 69). Liver fibrosis by FIB-4 was associated with risk of ICU admission (OR 1.74 [95%CI 1.74–2.68; p = 0.023]) and mortality (OR 6.45 [95%CI 2.01−20.83, p = 0.002]); no independent associations were found. Conclusions: The prevalence of steatosis and significant liver fibrosis was high in COVID-19 patients but was not associated with clinical outcomes.